They may target “innate” subsets engaged in cancer immune responses, such as NK cells (58), and/or exploit suppression via alternative signalings, such as the PD-1/PDL-1 axis (59, 60), with a potential impact on cancer immunotherapy (61, 62). This evidence concerns the gene CD274 and cancer.